Medication-induced dystonias in nine patients with dementia

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 12, Issue 2, 2000, Pages 219-225

  Magnuson, Thomas M ^a,b   Roccaforte, William H ^a   Wengel, Steven P ^a   Burke, William J ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOXAPINE; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DEMENTIA; DISEASE CLASSIFICATION; DYSTONIA; FEMALE; HUMAN; HYPERSALIVATION; MALE; PRIORITY JOURNAL;

EID: 0034028607     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.12.2.219     Document Type: Article

References (34)

1. Lishman WA: Organic Psychiatry: The Psychological Consequences of Cerebral Disorder, 3rd edition. Oxford, UK, Blackwell Science, 1998
2. Burke RE, Fahn S, Jankovic J, et al: Tardive dystonia: late onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982; 32:1335-1346
3. Gilmore R: Movement disorders in the elderly. Geriatrics 1984; 39:65-76
4. Addonizio G, Alexopoulos GS: Drug-induced dystonia in young and elderly patients. Am J Psychiatry 1988; 145:869-871
5. Rupniak NMJ, Jenner P, Marsden CD: Acute dystonia induced by neuroleptic drugs. Psychopharmacology 1986; 88:403-419
6. Marsden CD, Jenner P: The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 1980; 10:55-72
7. Casey DE: Motor and mental aspects of acute extrapyramidal syndromes. Acta Psychiatr Scand 1994; 89(suppl 380):14-20
8. Wirshirig WC, Marder SR, Van Puten T, et al: Acute treatment of schizophrenia, in Psychopharmacology: The Fourth Generation of Progress, edited by Bloom FE, Kupfer DJ. New York, Raven, 1995, pp 1259-1266
9. Barnes TR, McPhillips MA: Novel antipsychotic side effects and tardive dyskinesia. Int Clin Psychopharmacol 1998; 13(suppl 3):549-557
10. Sramek JJ, Simpson GM, Morison RL, et al: Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: a prospective study. J Clin Psychiatry 1986; 47:305-309
11. Fahn S, Eldridge R: Definition of dystonia and classification of the dystonic states. Adv Neurol 1976; 14:1-5
12. Snyder S, Greenberg D, Yamamura H: Antischizophrenic drugs and brain cholinergic receptors. Arch Gen Psychiatry 1974; 31:58-61
13. Yassa R, Nair V, Dimitry R: Prevalence of tardive dystonia. Acta Psychiatr Scand 1986; 73:629-633
14. Sachdev P: The prevalence of tardive dystonia in patients with chronic schizophrenia (letter). Aust NZ J Psychiatry 1991; 25:446-148
15. Kang UJ, Burke RE, Fahn S: Tardive dystonia. Adv Neurol 1988; 50:415-429
16. Kang UJ, Burke RE, Fahn S: Natural history and treatment of tardive dystonia. Mov Disord 1986; 1:193-208
17. Kiriakakis V, Bhatia KP, Quinn NP, et al: The natural history of tardive dystonia: a long-term follow-up study of 107 cases. Brain 1998; 121:2053-2066
18. Miller LG, Jankovic J: Drug-induced dyskinesias: an overview, in Movement Disorders in Neurology and Neuropsychiatry, 2nd edition, edited by Joseph A, Young R, Maiden MA. Boston, Blackwell Science, 1999, pp 5-30
19. Jenner P, Marsden CD: Adaptive changes in brain dopamine function as a result of neuroleptic treatment. Adv Neurol 1988; 44:417-431
20. Yassa R, Nastase C, Dupont D, et al: Tardive dyskinesia in elderly psychiatric patients: a five year study. Am J Psychiatry 1992; 149:1206-1211
21. Wojcik JD, Falk WE, Fink JS, et al: A review of 32 cases of tardive dystonia. Am J Psychiatry 1991; 148:1055-1059
22. Meltzer HY: The role of serotonin in the mechanism of action of antipsychotic drugs: does 5-HT also have a role in the etiology of schizophrenia? Schizophr Res 1989; 2:212-213
23. Chouinard G, Jones B, Remington G: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and halo-peridol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13:36S-44S
24. Katz IR, Jeste DV, Mintzer JE, et al: Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999; 60:107-115
25. Magnuson TM, Keller BK, Burke WJ: Extrapyramidal side-effects in a patient treated with risperidone plus donepezil (letter). Am J Psychiatry 1998; 155:1458-1459
26. Vercueil L, Foucher J: Risperidone-induced tardive dystonia and psychosis (letter). Lancet 1999; 553:881
27. 2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry 1997; 154:1525-1529
28. Branchey MH, Lee JH, Simpson GM: Loxapine succinate as a neuroleptic agent: evaluation in two populations of elderly psychiatric patients. J Am Geriatr Soc 1978; 26:263-267
29. Cadet JL, Lohr JB: Possible involvement of free radicals in neuroleptic movement disorders: evidence from treatment of tardive dyskinesia with vitamin E. Ann NY Acad Sci 1989; 570:176-185
30. Desci L: Further studies on the metabolic background of tranquilizing drug action. Psychopharmacologia 1961; 2:224-242
31. Richter D: Mode of action of the phenothiazines, in The Scientific Basis of Drug Therapy in Psychiatry, edited by Marks J, Pare CMB. Oxford, UK, Pergamon, 1965, pp 63-69
32. Nielson EB, Lyon M: Evidence for cell loss in the corpus striatum after long-term treatment with a neuroleptic drug (flupenthixol) in rats. Psychopharmacology 1978; 59:85-89
33. Weiner WJ, Nausieda PA, Klawans HL: Effects of chlorpromazine on central nervous system concentrations of manganese, iron and copper. Life Sci 1977; 20:1181-1186
34. McKeith IG, Fairbairn AF, Perry RH, et al: Neuroleptic sensitivity in patients with dementia of Lewy body type. BMJ 1992; 305:673-678